Passive immunization

Primary Care - Clinics in Office Practice

Volumn 38, Issue 4, 2011, Pages 681-691

  Raab, Christopher P ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Botulism; Cytomegalovirus; Hepatitis B; Immunization; Rabies; Respiratory syncytial virus; Tetanus

Indexed keywords

BOTULINUM ANTISERUM; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HEPATITIS B ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; RABIES IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; TETANUS ANTIBODY;

ANTIBODY TITER; BOTULISM; CHICKENPOX; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFLAMMATORY DISEASE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PASSIVE IMMUNIZATION; PERINATAL INFECTION; POST EXPOSURE PROPHYLAXIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RABIES; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEIZURE; TETANUS; UNSPECIFIED SIDE EFFECT; VACCINATION;

HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 81255210956     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.07.006     Document Type: Review

References (45)

1. Stevens C.E., Beasley R.P., Tsui J., et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771.
2. Previsani N., Lavanchy D., Zuckerman A.J., et al. Viral hepatitis. Perspectives in medical virology 2003, 31-98. Elsevier, Amsterdam. I.K. Mushawar (Ed.).
3. Mast E., Margolis H., Fiore A., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States, recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(RR16):1-23.
4. Lee C., Gong Y., Brok J., et al. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006, 2:CD004790.
5. Markowitz J.S., Martin P., Conrad A.J., et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination of lamivudine and hepatitis B immune globulin. Hepatology 1998, 28:585-589.
6. Wong S.N., Chu C.J., Wai C.T., et al. Low-risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007, 13:374-381.
7. Buti M., Mas A., Prieto M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis immunoglobulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003, 38:811-817.
8. Buti M., Mas A., Prieto M., et al. Adherence to lamivudine after an early withdrawal of hepatitis immunoglobulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007, 84:650-654.
9. Patterson S.J., Angus P.W. Postliver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009, 14:225-230.
10. Marin M., Guris D., Chaves S.S., et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR04):1-40.
11. Funkhouser W.L. The use of gamma globulin antibodies to control chickenpox in a convalescent hospital for children. J Pediatr 1948, 32:257-259.
12. Zaia J.A., Levin M.J., Preblud S.R., et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983, 147:737.
13. Centers for Disease Control A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006, 55:209-210.
14. American Academy of Pediatrics. Red Book: 2006 Report of the Committee on Infectious Diseases 2006, American Academy of Pediatrics, Elk Grove Village (IL). 27th editon. L.K. Pickering, C.J. Baker, S.S. Long (Eds.).
15. Babes V., Lepp M. Recherches sur la vaccination antirabique. Ann Inst Pasteur 1889, 3:385-390. [in French].
16. Stiehm E., Keller M. Rabies and rabies immune globulin. Feigin and Cherry's textbook of pediatric infectious disease 2009, 3430-3431. Saunders, Philadelphia. 6th edition. R.D. Feigin (Ed.).
17. Baltazard M., Bahmanyar M. Essai pratique du serum antirabique chez les mordus par loups enfantes. Bull World Health Organ 1955, 13:747-772. [in French].
18. World Health Organization. Wkly Epidemiol Rec 2010, 85:309-320.
19. American Academy of Pediatrics. Rabies. Red Book: 2006 Report of the Committee on Infectious Diseases 2006, 552-559. American Academy of Pediatrics, Elk Grove Village (IL). 27th editon. L.K. Pickering (Ed.).
20. World Health Organization WHO recommendations on rabies postexposure treatment and the correct technique, part 1. Guide for rabies postexposure treatment 1997, World Health Organization, Geneva (Switzerland).
21. Patel J.C., Mehta B.C., Nanavati B.H., et al. Role of serum therapy in tetanus. Lancet 1963, 1:740-743.
22. American Academy of Pediatrics. Tetanus (Lockjaw). Red Book: 2006 Report of the Committee on Infectious Diseases 2006, 648-653. American Academy of Pediatrics, Elk Grove Village (IL). 27th editon. L.K. Pickering (Ed.).
23. Begue R.E., Lindo-Soriano I. Failure of intrathecal tetanus antitoxin in the treatment of tetanus neonatorum. J Infect Dis 1991, 164:619-620.
24. Gupta P.S., Kapoor R., Goyal S., et al. Intrathecal human tetanus immunoglobulin in early tetanus. Lancet 1980, 2:439-440.
25. Snydman D.R., Werner B.G., Heinze-Lacey B., et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987, 317:1049-1054.
26. Falagas M.E., Snydman D.R., Ruthazer R., et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transplant 1997, 11:432-437.
27. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001, 3:44-48.
28. Weill D., Lock B.J., Wewers D.L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003, 3:492-496.
29. Ruutu T., Ljungman P., Brinch L., et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 1997, 19:233-236.
30. Cytomegalovirus prophylaxis following Solid Organ Transplants Guideteam, Cincinnati Children's Hospital Medical Center: Evidence-based care guideline for CMV Prophylaxis following Solid Organ Transplant. Available at: Accessed March 3, 2011. Guideline 17, July 6, 2007. p. 1-16. http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/cmv-transplant.htm.
31. Snydman D.R., Falagas M.E., Avery R., et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001, 33:2571-2575.
32. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006, 81:1415-1420.
33. Reed E.C., Bowden R.A., Dandliker P.S., et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988, 109:783-788.
34. Paar D.P., Pollard R.B. Immunotherapy of CMV infections. Adv Exp Med Biol 1996, 394:145-151.
35. Nigro G., Adler S.P., La Torre R., et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005, 353:1350-1362. 422.
36. Negishi H., Yamada H., Hirayama E., et al. Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. J Perinatol 1998, 18:466-469.
37. American Academy of Pediatrics. Botulism and infant botulism. Red Book: 2006 Report of the Committee on Infectious Diseases 2006, 259. American Academy of Pediatrics, Elk Grove Village (IL). 27th editon. L.K. Pickering (Ed.).
38. Meissner H.C., Bocchini J. Reducing RSV hospitalizations, AAP modifies recommendations for use of palivizumab in high-risk infants, young children. AAP News 2009, 30(7):1.
39. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93.
40. Groothius J.R., Simoes E.A., Levin M.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993, 329:1524.
41. The IMpact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
42. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998, 102(5):1211-1216.
43. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532.
44. American Academy of Pediatrics Committee on Infectious Diseases Policy statement-modified recommendations for use of palivizumab for the prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1684-1701.
45. Carbonell-Estrany X., Simões E.A., Dagan R., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125:e35-e51.